Literature DB >> 21453788

Sero-prevalence of mumps antibodies in subpopulations subsequently affected by a large scale mumps epidemic in Israel.

Khitam Muhsen1, Tamy Shohat, Yair Aboudy, Ella Mendelson, Nurit Algor, Emilia Anis, Dani Cohen.   

Abstract

BACKGROUND AND AIMS: Despite the high national vaccination coverage, a large outbreak of mumps occurred in Israel, in 2009-2010, with onset and heavy transmission in ultraorthodox Jewish communities and further country-wide spread. We examined the sero-prevalence of mumps antibodies in the subpopulations subsequently affected by this large mumps outbreak, compared with the general population.
METHODS: The study was conducted in ultraorthodox Jewish communities, in Jerusalem district (N=251), in Bnei Brak city in Tel Aviv district (N=453), and in the general population (N=1846), using residual sera of 1-20 year old subjects. Mumps IgG antibodies were measured using Enzygnost anti-parotitis virus IgG ELISA kit.
RESULTS: Mumps sero-positivity was significantly lower in Jerusalem: 51.8% (95% CI 51.9-61.0), and Bnei Brak: 56.5% (95% CI 45.6-57.9), than in the general population: 68.1% (95% CI 66.0-70.2). Sero-positivity increased with age, however in Jerusalem it was substantially low (46%) in the age group 10-20 years. This age group comprised a significant portion of mumps patients in the 2009-2010 outbreak.
CONCLUSIONS: Low immunity levels, combined with overcrowding and social mixing, were the main predisposing factors of the enhanced epidemic transmission of mumps in the ultraorthodox Jewish communities and further country-wide spread.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21453788     DOI: 10.1016/j.vaccine.2011.03.047

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Estimation of vaccine efficacy and critical vaccination coverage in partially observed outbreaks.

Authors:  Michiel van Boven; Wilhelmina L M Ruijs; Jacco Wallinga; Philip D O'Neill; Susan Hahné
Journal:  PLoS Comput Biol       Date:  2013-05-02       Impact factor: 4.475

Review 2.  Mumps in the Vaccination Age: Global Epidemiology and the Situation in Germany.

Authors:  Andrea-Ioana Beleni; Stefan Borgmann
Journal:  Int J Environ Res Public Health       Date:  2018-07-31       Impact factor: 3.390

3.  High risk of mumps infection in children who received one dose of mumps-containing vaccine: waning immunity to mumps in children aged 2-5 years from kindergartens in Jiangsu Province, China.

Authors:  Xiang Sun; Fenyang Tang; Ying Hu; Xiuying Deng; Zhiguo Wang; Minghao Zhou; Yuanbao Liu
Journal:  Hum Vaccin Immunother       Date:  2020-01-24       Impact factor: 3.452

4.  Seroprevalence of measles-, mumps- and rubella-specific IgG antibodies in German children and adolescents and predictors for seronegativity.

Authors:  Christina Poethko-Müller; Annette Mankertz
Journal:  PLoS One       Date:  2012-08-06       Impact factor: 3.240

5.  Difficulties in eliminating measles and controlling rubella and mumps: a cross-sectional study of a first measles and rubella vaccination and a second measles, mumps, and rubella vaccination.

Authors:  Zhifang Wang; Rui Yan; Hanqing He; Qian Li; Guohua Chen; Shengxu Yang; Enfu Chen
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.